Moderna, Inc. (MRNA)$46.88
Market Cap: 10.77 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Moderna, Inc. (MRNA).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
-4.0x
EV/FCF, N/A FCF yield
Quality
-32.6%
ROIC, -106.2% FCF margin
Growth
19.3%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 3.3x current ratio
Superinvestors
0
No tracked positions
Strengths to research
- Revenue compounded at 19.3% over five years.
- Debt/equity looks manageable at 0.0x.
- 10 annual periods are available for trend analysis.
Watchouts
- Free cash flow margin is negative at -106.2%.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for MRNA.
Grade F
23
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| MRNA Target | Moderna, Inc. | $10.8B | -6.5x | -4.0x | -32.6% | 19.3% | -106.2% | N/A | N/A | N/A |
| BMRN | BioMarin Pharmaceutical Inc. | $11.9B | 30.1x | 14.6x | 5.7% | 11.6% | 22.5% | N/A | -2.7x | N/A |
| INCY | Incyte Corp. | $12.0B | 15.2x | 6.3x | 24.9% | 14.0% | 27.5% | N/A | -1.9x | N/A |
| ROIV | Roivant Sciences Ltd | $8.3B | -55.5x | -9.0x | -6.6% | -19.1% | -9183.5% | N/A | N/A | N/A |
| TECH | Bio-Techne Corp. | $7.9B | 104.8x | 30.1x | 3.8% | 10.5% | 21.0% | 64.8% | -0.8x | N/A |
| HALO | Halozyme Therapeutics | $7.5B | 26.7x | 14.7x | 14.5% | 39.2% | 46.2% | N/A | 4.2x | N/A |
| BBIO | BridgeBio Pharma Inc. | $7.3B | -18.3x | -19.5x | N/A | 127.4% | -89.0% | N/A | N/A | N/A |
| LEGN | Legend Biotech Corp. | $6.1B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| RPRX | Royalty Pharma plc | $19.0B | 30.6x | 11.0x | 4.1% | 2.3% | 104.7% | N/A | 5.3x | N/A |
Financial Charts
No financial data available for MRNA (annual).